New study tracks TAKHZYRO's safety for HAE patients in japan
NCT ID NCT05397431
First seen Feb 04, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study looks at the long-term safety and symptom control of TAKHZYRO (lanadelumab) in 155 people with hereditary angioedema (HAE) in Japan. Participants receive the injection as part of their normal care, and doctors monitor side effects and quality of life for 12 months. The goal is to understand how well the drug works in everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Takeda selected site
Tokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.